
We Claim:

1. A compound of formula (I):



(I)

wherein,

X and Y are selected from the group consisting of hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, trifluoromethoxy, morpholin-4-yl-methanone such that not two of the subtituents are hydrogen at the same time;

R^1 is H or optionally substituted (C_1-C_4)-alkyl;

R^2 is selected from the group comprising, hydrogen and natural and unnatural amino acids;

an N-oxide of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound or a hydrate of said compound.

2. The compound in claim 1 wherein R^2 is selected from the group consisting of hydrogen and $-C(O)CH(CH(CH_3)_2)NH_2$.

3. The compound in claim 2 in which X is $-OCF_3$.

4. The compound in claim 2 in which X is morpholin-4-yl-methanone.

5. The compound in claim 1 in which R^1 is isopropyl.

6. The compound in claim 1 which is selected from the group consisting of:

(S)-2-Amino-N-[(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-methyl]-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(R)-2-Amino-N-(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-[(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-methyl]-3-methyl-butyramide hydrochloride,
(R)-2-Amino-N-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride, and
(S)-2-Amino-N-[(S)-1-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-2-methyl-propyl]-3-methyl-butyramide hydrochloride.

7. A pharmaceutical composition comprising one or more of compounds of formula 1 as recited in claim 1 in a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising one or more of compounds of formula 1 as recited in claim 1 and one or more additional pharmaceutically active compounds which are useful in the treatment of inflammatory diseases.

9. A pharmaceutical composition as recited in claim 8 in a pharmaceutically acceptable carrier.

10. The pharmaceutical composition in claim 8 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of known anti-inflammatory agents.

11. The pharmaceutical composition in claim 10 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of compounds known to treat airway inflammation.

12. The pharmaceutical composition in claim 10 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of compounds known to treat joint inflammation.

13. The pharmaceutical composition in claim 7 for the treatment of physiological condition, wherein the physiological condition is selected from the group consisting of inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung disease, fibrosis, chronic obstructive pulmonary disease, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibroma, hypertrophic scar, dermatological condition, condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcer, and syncytial viral infection.


14. A method of treatment and/or prevention of inflammatory diseases by the administration of a composition comprising one or more of the compounds of formula 1 as recited in claim 1.

15. A method of treatment and/or prevention of inflammatory diseases as recited in claim 14 wherein the composition further comprises a pharmaceutically acceptable carrier.

16. A method of treatment and/or prevention of inflammatory diseases as recited in claim 15 wherein the composition further comprises a known anti-inflammatory agent.

CLAIMS

1. A compound of formula (I):



(I)

wherein,

X and Y are selected from the group consisting of hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, trifluoromethoxy, morpholin-4-yl-methanone such that not two of the subtituents are hydrogen at the same time;

R^1 is H, lower alkyl or substituted alkyl;

R^2 is selected from the group comprising, hydrogen and natural and unnatural amino acids;

an N-oxide of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound or a hydrate of said compound.

2. The compound in claim 1 wherein R^2 is selected from the group consisting of hydrogen and $-C(O)CH(CH(CH_3)_2)NH_2$.

3. The compound in claim 2 in which X is $-OCF_3$.

4. The compound in claim 2 in which X is morpholin-4-yl-methanone.

5. The compound in claim 1 in which R^1 is isopropyl.

6. The compound in claim 1 which is selected from the group consisting of:

(S)-2-Amino-N-[(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-methyl]-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(R)-2-Amino-N-(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride,
(S)-2-Amino-N-[(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-methyl]-3-methyl-butyramide hydrochloride,
(R)-2-Amino-N-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-3-methyl-butyramide hydrochloride, and
(S)-2-Amino-N-[(S)-1-(4-fluoro-3-{1-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-2-methyl-propyl]-3-methyl-butyramide hydrochloride.

7. A pharmaceutical composition comprising one or more of compounds of formula 1 as recited in claim 1 in a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising one or more of compounds of formula 1 as recited in claim 1 and one or more additional pharmaceutically active compounds which are useful in the treatment of inflammatory diseases.

9. A pharmaceutical composition as recited in claim 8 in a pharmaceutically acceptable carrier.

10. The pharmaceutical composition in claim 8 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of known anti-inflammatory agents.

11. The pharmaceutical composition in claim 10 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of compounds known to treat airway inflammation.

12. The pharmaceutical composition in claim 10 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of compounds known to treat joint inflammation.

13. A compound of formula I as recited in claim 1 for use in treatment and/or prevention of inflammatory diseases.

14. A compound of formula 1 according to claim 13 characterized in that it is administered with a pharmaceutically acceptable carrier.

15. A compound of formula 1 according to claim 13 characterized in that it is administered together with a known anti-inflammatory agent and a pharmaceutically acceptable carrier.